Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Phase 1 Coming Soon

<< Previous

Bullboard Posts

Next >>

Comment by PTBaileyon Mar 19, 2022 1:41am

165 Views

Post# 34527420

RE:RE:Phase 1 Coming Soon

There is ample info posted as to why the delays of phase 1 have happened so no need to explain it any more.

Only a matter of time because at this point the submissions to ethics committee are minor and should be approved anytime.

I expect to lose my B warrants but to more than make up for it on the shares I have.

Based on this post I don't think I will provide the emai address you will have to figure that out on your own.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario